Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

CIBC World Lowers Genentech to 'Sector Perform'

CIBC World downgraded Genentech (DNA) to sector perform from sector outperform.

Analyst Matt Geller says the downgrade is based on roughly $12 billion appreciation in Genentech's shares since May 19, when the company that its experimental drug Avastin improved the survival of colorectal cancer patients when used with chemotherapy. He believes the recent rally reflects $1.5 billion to $2 billion in peak Avistin sales. Based solely on the current information, he doesn't see any clear upside from here.

Still, Geller regards Genentech highly, but with recent appreciation, and believes there are better short- to intermediate-term opportunities. As of today, he dropped the $53 12-month to 18-month target.

blog comments powered by Disqus